Chronic pulmonary complications of haematopoietic SCTs (HSCTs) include interstitial disease and bronchiolitis obliterans (BO). BO almost exclusively occurs in allograft recipients (usually 12 months post HSCT 1, 2 ) and is closely associated with chronic GvHD and a poorer outcome post HSCT. Identified risk factors for BO include older age of recipient/donor, pre-transplant lung function abnormalities, female donor for male patients and low levels of IgG. [1] [2] [3] The proportion of HSCT recipients developing lung GvHD varies from 1 to 40% [1] [2] [3] [4] among studies. More accurate data are required for planning controlled trials of treatments such as azithromycin, which is an effective treatment for BO post lung transplantation. 5, 6 We have therefore performed a retrospective study to estimate the current UK prevalence of new lung function impairment following allogeneic HSCT to help plan future prospective studies of aetiological associations or therapies for lung GvHD.
We retrospectively reviewed the British Society of Blood and Marrow Transplantation database for patients ⩾ 18 years undergoing first-time allogeneic HSCT between 2004 and 2007. Six UK centres participated and only patients with pulmonary function tests (PFTs) obtained o3 months prior to HSCT were included. Demographic, diagnosis, transplant type, conditioning treatment and PFT data were collected. Post-HSCT data were obtained from PFT recorded between 12 month and 24 months post transplant. Impaired lung function was defined as forced expiratory volume for 1s (FEV 1 ) or forced vital capacity (FVC) o80% predicted. Lung function defects were defined as: obstructive FEV 1 /FVC ratioo 70%; probable restrictive FEV 1 /FVC ratio 480% (lung volumes were not available); and mixed-pattern FEV 1 /FVC ratio 70-80%. Two-sided P-values were calculated using Stata 11 and 95% was used as the significance level.
Of 4022 allogeneic transplants registered over the study period, 532 were performed at participating centres of which 157 had pre-HSCT PFTs. Of these 90 had PFT data collected 12-24 months post HSCT. There were no significant differences in demography and clinical background between patients with pre-HSCT data and those with pre-and 12 month data (Table 1) . For patients with preand post-HSCT PFT data, 76 (84%) had normal and only 14 (16%) had abnormal PFTs pre-HSCT (Table 2 ). Post HSCT, the lung function of 63 (83%) patients remained unimpaired, with 13 (17%) patients developing new PFT abnormalities (FEV 1 or FVC o 80% predicted). Of these 13 patients, 12 had a 415% fall in pre-HSCT FEV 1 and FVC, and the median reductions in predicted FEV 1 and FVC were 33.5% (10.8-73.5%) and 28.9% (IQR 4-53%) ( Table 2 ). The pattern of new PFT abnormalities was obstructive in five (38%) patients, probable restrictive in six (46%) patients, and mixed pattern in two (16%) patients. CT scan reports were available for nine patients; four demonstrated bronchial dilatation, two centrilobular nodularity (both potentially consistent with lung GvHD), and three lung fibrosis. Of the 63 patients whose PFTS remained 480% predicted, 42 (67%) had a decrease in FEV 1 and/ or FVC post HSCT, including 15 (24%) with a ⩾ 15% fall in FEV 1 (16 ⩽ 5% and 12 ⩽ 10% fall), 14 (22%) ⩾ 15% fall in FVC (17 ⩽ 5% and 12 ⩽ 10% fall), and 6 with a ⩾ 15% fall in both FEV 1 and FVC.
Acute GvHD was noted in 9 (69%) patients with newly impaired PFTs compared to 25 (40%) with no post-HSCT impairment (P = 0.051). Chronic GvHD was observed in 80% (44/55, 8 unknown) of patients with unimpaired lung function post HSCT and 73% (8/11, 2 unknown) of patients with newly impaired lung function (P = 0.590). Age, sex, underlying diagnosis, transplant type, donor, and TBI were not associated with new lung function impairment. Of the 14 patients with impaired PFTs pre-HSCT, 11 (79%) were persistently impaired with no further significant fall in spirometry 12 months post HSCT and 3 improved to normal ( Table 2 ).
Our data suggest that 17% of HSCT recipients develop significant new lung function impairment, with a substantial median loss of FEV 1 at 33.5% over 12 months that, if untreated, could rapidly result in fatal respiratory failure. Both obstructive and probable restrictive changes were observed, indicating that BO is not the cause in all patients. Lung fibrosis due to chemotherapy, radiation or acute infection is an alternative potential contributor, but a detailed evaluation of the causes of these large falls in lung function post HSCT will require a prospective study. In addition to patients with new abnormal lung function post HSCT, many patients whose lung function remained within normal limits had a 415% reduction in FEV 1 or FVC. Whether these patients have less Abbreviations: FEV 1 = forced expiratory volume in 1s; FVC = forced vital capacity; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma. a Other diagnoses include myelodysplastic syndrome, myeloproliferative syndrome, chronic lymphocytic leukaemia, biphenotypic acute leukaemia, BM failure, BM aplasia, secondary AML, primary immune deficiency and multiple myeloma.
severe chronic lung disease such as BO or non-progressive or transient falls in lung function would also need prospective evaluation with repeated lung function. Overall, there were major changes in lung function in 38% of the patients for whom data were available.
This retrospective study has several major limitations, including low patient numbers, incomplete 12-month data, lack of clinical correlation and more detailed lung function data (for example, lung volumes and transfer factor). Importantly, selection bias may have increased the proportion of all patients with abnormal results as lung function tests may be more likely to be performed in patients with lung symptoms. Only 30% of patients in this study had pre-transplant PFTs, of which only 57% had data at 12 months. The limited availability of PFT data was surprising given HSCT guidelines recommend regular clinical assessment for lung complications and measurement of PFTs in patients with evidence of respiratory disease or in all patients with chronic GvHD. 7 As post-HSCT BO often presents clinically only after substantial loss of lung function, the low frequency of lung function testing is of concern. We suggest that closer adherence to lung function testing guidelines in HSCT patients may help us identify the patients developing BO at an earlier stage, when therapeutic intervention could be more effective. The upper 95% confidence interval for our data and the 2011 number of HSCT recipients (1314) suggests that up to 242 allograft HSCT recipients may develop major pulmonary impairment each year in the UK. This will be a major contributor to morbidity and mortality post SCT, and requires further detailed evaluation by prospective studies of lung function in a large number of unselected HSCT recipients. Abbreviations: FEV 1 = forced expiratory volume in 1s; FVC = forced vital capacity; HSCT = hematopoietic SCT.
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